Alexander W den Hartog

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.

Henk A Marquering, A. Zwinderman, A. W. den Hartog, 2013, European heart journal.

The risk for type B aortic dissection in Marfan syndrome.

A. Zwinderman, G. Pals, A. W. den Hartog, 2015, Journal of the American College of Cardiology.

No Beneficial Effect of General and Specific Anti-Inflammatory Therapies on Aortic Dilatation in Marfan Mice

A. Zwinderman, R. Franken, V. de Waard, 2014, PloS one.

Aortic disease in patients with Marfan syndrome: aortic volume assessment for surveillance.

A. Zwinderman, A. W. den Hartog, R. Franken, 2013, Radiology.

Clinical features differ substantially between Caucasian and Asian populations of Marfan syndrome.

A. Zwinderman, A. W. den Hartog, R. Franken, 2013, Circulation journal : official journal of the Japanese Circulation Society.

Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome.

A. Zwinderman, R. Franken, J. Timmermans, 2013, International journal of cardiology.

Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome

A. Zwinderman, R. Franken, J. Timmermans, 2015, Circulation. Cardiovascular genetics.

First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study

M. Beijk, B. Claessen, R. Delewi, 2023, Journal of clinical medicine.

Recurrent syncope due to glossopharyngeal neuralgia

A. W. den Hartog, P. van den Munckhof, J. D. de Jong, 2016, HeartRhythm case reports.

Paclitaxel-coated balloons for vulnerable lipid-rich plaques.

H. Garcia-Garcia, B. Claessen, R. Delewi, 2024, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal?

M. Beijk, A. W. den Hartog, B. Claessen, 2022, Expert review of cardiovascular therapy.